Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma

Most melanomas have BRAF V600E/K mutations, making V600 an important target for precision treatment of melanoma, and it can often be blocked by a combination of BRAF inhibitors and MEK inhibitors. The emergence of immune checkpoint inhibitors has also greatly improved the treatment outcome of patients with BRAF V600 mutation-positive advanced melanoma. Clinical trials are also underway to determine the best first-line treatment and the sequence of combination therapies for these patients. This paper reviewed the latest progress in the treatment of BRAF V600 mutation-positive advanced melanoma in the era of precision medicine.